• The electronic drug registration system (eDRS) in China has significantly improved the efficiency and transparency of drug approvals.
• Integration of eDRS with pharmacovigilance and clinical trial databases enhances post-market drug safety monitoring.
• Challenges such as data standardization and interoperability remain, necessitating ongoing system optimization.
• Adoption of emerging technologies like AI and blockchain can further strengthen the eDRS's integrity and security.